US2023399401A1PendingUtilityA1
Optimized antibody variable regions
Est. expiryJan 14, 2033(~6.5 yrs left)· nominal 20-yr term from priority
C07K 16/2803C07K 16/2809C07K 16/468C07K 16/00C07K 1/18C07K 2317/62C07K 2317/31C07K 2317/565C07K 2317/622C07K 2317/55C07K 2317/64C07K 2317/94
83
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
Claims
exact text as granted — not AI-modified1 .- 83 . (canceled)
84 . A construct comprising an anti-CD3 binding domain, said anti-CD3 binding domain comprising a variable heavy chain having at least 95% identity to the amino acid sequence of SEQ ID NO: 397 and a variable light chain having at least 95% identity to the amino acid sequence of SEQ ID NO: 398.Join the waitlist — get patent alerts
Track US2023399401A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.